Chemical degradation of Human p38-MAPK reveals it as a potential host target to combat parasitic infections by Leishmania donovani and Plasmodium falciparum - PubMed
5 hours ago
- #parasitic infections
- #p38-MAPK
- #PROTAC therapy
- NR-7h, a PROTAC targeting human p38-MAPK, degrades p38-MAPK in host cells in a time- and dose-dependent manner.
- Degradation of host p38-MAPK by NR-7h reduces parasite load in Leishmania donovani and Plasmodium falciparum infections, implicating its role in parasite survival.
- In Leishmania infection, NR-7h-mediated p38-MAPK degradation alters cytokine profiling and oxidative burst, correlating with parasite death, and enhances Amphotericin B efficacy.
- For Plasmodium, host p38-MAPK degradation impairs merozoite invasion and intraerythrocytic development, indicating its involvement in parasite invasion and growth.
- Host p38-MAPK is a potential therapeutic target for combating parasitic infections using targeted degradation approaches like NR-7h.